Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Middle East Pharmaceutical Industries CoSAU:4016 -0.67%22 Return-on-Tangible-Asset is 19.56% as of Mar. 2026, which is 8% above its 10-year median of 18.10. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks better than 93.64% on this metric.
SAU:4016'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 16.22 Med: 18.1 Max: 20.02
Current: 20.02
During the past 3 years, Middle East Pharmaceutical Industries Co's highest Return-on-Tangible-Asset was 20.02%. The lowest was 16.22%. And the median was 18.10%.
SAU:4016's Return-on-Tangible-Asset is ranked better than 93.64% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.015
vs SAU:4016: 20.02
Middle East Pharmaceutical Industries Co (SAU:4016) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Middle East Pharmaceutical Industries Co Return-on-Tangible-Asset Related Terms
Middle East Pharmaceutical Industries Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co Return-on-Tangible-Asset Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
Return-on-Tangible-Asset
16.22
18.10
19.15
Middle East Pharmaceutical Industries Co Quarterly Data
SAU:4016 vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Middle East Pharmaceutical Industries Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Middle East Pharmaceutical Industries Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 19.56% mean?
Middle East Pharmaceutical Industries Co (SAU:4016) has a Return-on-Tangible-Asset of 19.56% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Middle East Pharmaceutical Industries Co and its competitors. This is near median its historical median of 18.10. Over the past decade, Middle East Pharmaceutical Industries Co's Return-on-Tangible-Asset has ranged from 16.22 to 20.02. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #64 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 6.4%.
Is Middle East Pharmaceutical Industries Co's Return-on-Tangible-Asset too high?
Middle East Pharmaceutical Industries Co's current Return-on-Tangible-Asset of 19.56% is near median its 10-year median of 18.10. Over the past 10 years, this metric has ranged from a low of 16.22 to a high of 20.02. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.02. Middle East Pharmaceutical Industries Co's value of 19.56% is 548.8% above this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #64 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #64 out of 1006 companies for Return-on-Tangible-Asset. This places Middle East Pharmaceutical Industries Co in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.02. Middle East Pharmaceutical Industries Co's value of 19.56% is 548.8% above this benchmark. Historically, Middle East Pharmaceutical Industries Co's own Return-on-Tangible-Asset has ranged from 16.22 to 20.02 over the past decade. While the company's 10-year median is 18.10 vs. the industry median of 3.02, Middle East Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.02, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current Return-on-Tangible-Asset of 19.56% is 548.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Middle East Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current Return-on-Tangible-Asset is 19.56%, which is near median its own 10-year median of 18.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current Return-on-Tangible-Asset of 19.56%. The current Return-on-Tangible-Asset is 19.56%, which is near median its 10-year median of 18.10 and 548.8% above the Drug Manufacturers industry median of 3.02. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current Return-on-Tangible-Asset is 19.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score
Get the complete analysis for SAU:4016
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
